INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 166 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $183,000 | +76.0% | 1,446 | +16.2% | 0.00% | +100.0% |
| Q2 2018 | $104,000 | +35.1% | 1,244 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $77,000 | +2.7% | 1,244 | -3.1% | 0.00% | 0.0% |
| Q4 2017 | $75,000 | -8.5% | 1,284 | -9.4% | 0.00% | 0.0% |
| Q3 2017 | $82,000 | -44.2% | 1,417 | +16.5% | 0.00% | -50.0% |
| Q2 2017 | $147,000 | -2.0% | 1,216 | -8.1% | 0.00% | -33.3% |
| Q1 2017 | $150,000 | -3.8% | 1,323 | -8.1% | 0.00% | 0.0% |
| Q4 2016 | $156,000 | -75.0% | 1,439 | -62.1% | 0.00% | -72.7% |
| Q3 2016 | $625,000 | +15.3% | 3,800 | 0.0% | 0.01% | +10.0% |
| Q2 2016 | $542,000 | +11.1% | 3,800 | 0.0% | 0.01% | +11.1% |
| Q1 2016 | $488,000 | -14.1% | 3,800 | 0.0% | 0.01% | -10.0% |
| Q4 2015 | $568,000 | +2.0% | 3,800 | +13.1% | 0.01% | +11.1% |
| Q3 2015 | $557,000 | -65.1% | 3,360 | -49.1% | 0.01% | -18.2% |
| Q2 2015 | $1,594,000 | – | 6,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |